Physician profile
Carmen Lam
NPI 1477904837
$3,997.86
in general payments reported to CMS, 2019-2025
45 companies · $1,080 in 2025
The $1,080 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $10.50 · 2022: $1,406 · 2023: $422 · 2024: $946 · 2025: $1,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,447.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,140.12 | 2022-2025 | Molli, Spy-Phi System |
| Merck Sharp & Dohme LLC | $240.48 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Takeda Pharmaceuticals U.S.A., INC. | $227.18 | 2023-2025 | Alunbrig, Ninlaro, Iclusig |
| Davol INC. | $169.59 | 2022-2025 | Phasix Mesh |
| Avanos Medical | $157.28 | 2023-2025 | On-Q* Pump and Accessories, On-Q Pump and Accessories |
| Astrazeneca Pharmaceuticals LP | $152.49 | 2024-2025 | Calquence, Enhertu |
| Regeneron Healthcare Solutions, INC. | $152.42 | 2022-2025 | Libtayo |
| Janssen Biotech, INC. | $145.37 | 2024-2025 | Rybrevant, Darzalex, Tremfya |
| Novartis Pharmaceuticals Corporation | $137.65 | 2025 | |
| Bard Access Systems, INC. | $133.69 | 2019 | |
| Genzyme Corporation | $120.79 | 2022 | |
| Acera Surgical, INC. | $111.12 | 2024 | Restrata Wound Matrix |
| Stemline Therapeutics INC. | $97.85 | 2023-2025 | Orserdu |
| Pfizer INC. | $66.40 | 2023-2024 | |
| Pharmaessentia USA Corporation | $60.14 | 2025 | Besremi |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.